Caroline Aspord

Dr. Caroline Aspord

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2007 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
HUHideki Ueno
Hideki Ueno
EKEynav Klechevsky
Eynav Klechevsky
RMRimpei Morita
Rimpei Morita
CACaroline Aspord
Caroline Aspord
TCTinghua Cao
Tinghua Cao
JBJacques Banchereau
Jacques Banchereau

16 April 2007 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CACaroline Aspord
Caroline Aspord
APAlexander Pedroza-Gonzalez
Alexander Pedroza-Gonzalez
MGMike Gallegos
Mike Gallegos
STSasha Tindle
Sasha Tindle
EBElizabeth C. Burton
Elizabeth C. Burton
APA. Karolina Palucka
A. Karolina Palucka
We previously reported (Bell, D., P. Chomarat, D. Broyles, G. Netto, G.M. Harb, S. Lebecque, J. Valladeau, J. Davoust, K.A. Palucka, and J. Banchereau. 1999. J. Exp. Med. 190: 1417–1426) that breast cancer tumors are infiltrated with mature dendritic cells (DCs), which cluster with CD4+ T cells. We now show that CD4+ T cells infiltrating breast cancer tumors secrete type 1 (interferon γ) as well as high levels of type 2 (interleukin [IL] 4 and IL-13) cytokines. Immunofluorescence staining of tissue sections revealed intense IL-13 staining on breast cancer cells. The expression of phosphorylated signal transducer and activator of transcription 6 in breast cancer cells suggests that IL-13 actually delivers signals to cancer cells. To determine the link between breast cancer, DCs, and CD4+ T cells, we implanted human breast cancer cell lines in nonobese diabetic/LtSz-scid/scid β2 microglobulin–deficient mice engrafted with human CD34+ hematopoietic progenitor cells and autologous T cells. There, CD4+ T cells promote early tumor development. This is dependent on DCs and can be partially prevented by administration of IL-13 antagonists. Thus, breast cancer targets DCs to facilitate its development.

21 February 2011 in Journal of Experimental Medicine
Verified
Journal Article
Open access
APAlexander Pedroza-Gonzalez
Alexander Pedroza-Gonzalez
KXKangling Xu
Kangling Xu
TWTe-Chia Wu
Te-Chia Wu
CACaroline Aspord
Caroline Aspord
STSasha Tindle
Sasha Tindle
APA. Karolina Palucka
A. Karolina Palucka
The human breast tumor microenvironment can display features of T helper type 2 (Th2) inflammation, and Th2 inflammation can promote tumor development. However, the molecular and cellular mechanisms contributing to Th2 inflammation in breast tumors remain unclear. Here, we show that human breast cancer cells produce thymic stromal lymphopoietin (TSLP). Breast tumor supernatants, in a TSLP-dependent manner, induce expression of OX40L on dendritic cells (DCs). OX40L+ DCs are found in primary breast tumor infiltrates. OX40L+ DCs drive development of inflammatory Th2 cells producing interleukin-13 and tumor necrosis factor in vitro. Antibodies neutralizing TSLP or OX40L inhibit breast tumor growth and interleukin-13 production in a xenograft model. Thus, breast cancer cell–derived TSLP contributes to the inflammatory Th2 microenvironment conducive to breast tumor development by inducing OX40L expression on DCs.

1 December 2014 in The Journal of Immunology
Verified
Journal Article
Closed access
SLSophie Laffont-Pradines
Sophie Laffont-Pradines
NRNelly Rouquié
Nelly Rouquié
PAPascal Azar
Pascal Azar
CSCyril Seillet
Cyril Seillet
JPJoël Plumas
Joël Plumas
JGJean-Charles Guéry
Jean-Charles Guéry
Human plasmacytoid dendritic cells (pDCs) play a major role in innate immunity through the production of type I IFNs after TLR engagement by pathogens. Sex-based differences in the innate function of human pDCs have been established, with pDCs from women exhibiting enhanced TLR7-mediated IFN-α production as compared with pDCs from males. In mice, we recently provided evidence for a role of estrogens as a positive regulator of pDC innate functions through cell-intrinsic estrogen receptor α signaling, but did not exclude a role for other X-linked factors, particularly in human pDCs. In this study, we investigated the respective contribution of X chromosome dosage and sex hormones using a humanized mouse model in which male or female NOD-SCID-β2m−/− were transplanted with human progenitor cells purified from either male or female cord blood cells. We showed that, in response to TLR7 ligands, the frequency of IFN-α– and TNF-α–producing pDCs from either sex was greater in female than in male host mice, suggesting a positive role for estrogens. Indeed, blockade of estrogen receptor signaling during pDC development in vitro inhibited TLR7-mediated IFN-α production by human pDCs, which expressed both ESR1 and ESR2 genes. Interestingly, we also found that X chromosome dosage contributed to this sex bias as female pDCs have an enhanced TLR7-mediated IFN-α response as compared with male ones, irrespective of the sex of the recipient mice. Together, these results indicate that female sex hormones, estrogens, and X chromosome complement independently contribute to the enhanced TLR7-mediated IFN-α response of pDCs in women.

1 December 2013 in Cancer Immunology Research
Verified
Journal Article
Closed access
CACaroline Aspord
Caroline Aspord
MLMarie-Therese Leccia
Marie-Therese Leccia
JCJulie Charles
Julie Charles
JPJoel Plumas
Joel Plumas
Even though melanoma is considered to be one of the most immunogenic solid tumors, handling its development remains a challenge. The basis for such escape from antitumor immune control has not yet been documented. Plasmacytoid dendritic cells (pDC) are emerging as crucial but still enigmatic cells in cancer. In melanoma, the function of tumor-infiltrating pDCs remains poorly explored. We investigated the pathophysiologic role of pDCs in melanoma, both ex vivo from a large cohort of melanoma patients and in vivo in melanoma-bearing humanized mice. pDCs were found in high proportions in cutaneous melanoma and tumor-draining lymph nodes, yet associated with poor clinical outcome. We showed that pDCs migrating to the tumor microenvironment displayed particular features, subsequently promoting proinflammatory Th2 and regulatory immune profiles through OX40L and ICOSL expression. Elevated frequencies of interleukin (IL)-5-, IL-13- and IL-10–producing T cells in patients with melanoma correlated with high proportions of OX40L- and ICOSL-expressing pDCs. Strikingly TARC/CCL17, MDC/CCL22, and MMP-2 found in the melanoma microenvironment were associated with pDC accumulation, OX40L and ICOSL modulation, and/or early relapse. Thus, melanoma actively exploits pDC plasticity to promote its progression. By identifying novel insights into the mechanism of hijacking of immunity by melanoma, our study exposes potential for new therapeutic opportunities. Cancer Immunol Res; 1(6); 402–15. ©2013 AACR.

1 December 2012 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
JMJeremie Martinet
Jeremie Martinet
TDTania Dufeu–Duchesne
Tania Dufeu–Duchesne
JCJuliana Bruder Costa
Juliana Bruder Costa
SLSylvie Larrat
Sylvie Larrat
AMAlice Marlu
Alice Marlu
CACaroline Aspord
Caroline Aspord